Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
1 clinical trials · Condition
◉ Watch Resectable Gastric and Gastroesophageal Junction Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. (NCT03773367) | Lund University Hospital | 2018-12-14 |
Track Resectable Gastric and Gastroesophageal Junction Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.